Literature DB >> 2558631

Drug resistant rhinoviruses from the nose of experimentally treated volunteers.

C Dearden1, W al-Nakib, K Andries, R Woestenborghs, D A Tyrrell.   

Abstract

Viruses were isolated from nasal washings of volunteers receiving experimental therapy for rhinovirus type 9 infection with intranasal sprays of a new synthetic antiviral R61837. On a screening test nine subjects yielded drug sensitive virus and four resistant virus. In four others the virus was sensitive at first but became resistant later, while in one the reverse occurred. Evidence is given that at least some of the resistant viruses were present in the respiratory tract and were not selected during virus isolation. Of six viruses studied in detail, five had a low degree of resistance and one was highly resistant. The degree of resistance of the five was similar for an antiviral chalcone, dichloroflavan and disoxaril. The sixth was different in that the resistance to disoxaril was relatively less than to the other drugs. The significance of these results is discussed--these are the first experiments in man to show the selection of drug resistant rhinovirus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558631     DOI: 10.1007/BF01310519

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  12 in total

1.  Studies of rhinovirus resistant to an antiviral chalcone.

Authors:  A L Ahmad; A B Dowsett; D A Tyrrell
Journal:  Antiviral Res       Date:  1987-08       Impact factor: 5.970

2.  The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.

Authors:  T J Smith; M J Kremer; M Luo; G Vriend; E Arnold; G Kamer; M G Rossmann; M A McKinlay; G D Diana; M J Otto
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

Review 3.  Inhibitors of picornavirus uncoating as antiviral agents.

Authors:  G D Diana; M J Otto; M A McKinlay
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

4.  Some improved techniques for the study of rhinoviruses using HeLa cells.

Authors:  E J Stott; D A Tyrrell
Journal:  Arch Gesamte Virusforsch       Date:  1968

5.  Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers.

Authors:  W Al-Nakib; P G Higgins; I Barrow; D A Tyrrell; I Lenox-Smith; H Ishitsuka
Journal:  J Antimicrob Chemother       Date:  1987-12       Impact factor: 5.790

6.  Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B.

Authors:  M Tisdale; J W Selway
Journal:  J Antimicrob Chemother       Date:  1984-08       Impact factor: 5.790

7.  Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837).

Authors:  W al-Nakib; P G Higgins; G I Barrow; D A Tyrrell; K Andries; G Vanden Bussche; N Taylor; P A Janssen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  Failure of intranasally administered 4', 6-dichloroflavan to protect against rhinovirus infection in man.

Authors:  W Al-Nakib; J Willman; P G Higgins; D A Tyrrell; W M Shepherd; D S Freestone
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

9.  Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.

Authors:  Y Ninomiya; C Ohsawa; M Aoyama; I Umeda; Y Suhara; H Ishitsuka
Journal:  Virology       Date:  1984-04-30       Impact factor: 3.616

10.  In vitro activity of R 61837, a new antirhinovirus compound.

Authors:  K Andries; B Dewindt; M De Brabander; R Stokbroekx; P A Janssen
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

View more
  11 in total

Review 1.  Problems and prospects of developing effective therapy for common cold viruses.

Authors:  S L Johnston
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

2.  Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.

Authors:  Daniel C Pevear; Frederick G Hayden; Tina M Demenczuk; Linda R Barone; Mark A McKinlay; Marc S Collett
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 3.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  Intranasal pirodavir (R77,975) treatment of rhinovirus colds.

Authors:  F G Hayden; G J Hipskind; D H Woerner; G F Eisen; M Janssens; P A Janssen; K Andries
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection.

Authors:  R B Turner; F J Dutko; N H Goldstein; G Lockwood; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

6.  In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1.

Authors:  E Arruda; C E Crump; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

7.  Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.

Authors:  S R Yasin; W al-Nakib; D A Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates.

Authors:  A Ohlin; H Hoover-Litty; G Sanderson; A Paessens; S L Johnston; S T Holgate; E Huguenel; J M Greve
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection.

Authors:  F G Hayden; K Andries; P A Janssen
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 10.  Utility of animal and in vivo experimental infection of humans with rhinoviruses in the development of therapeutic agents for viral exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  Alfred M Del Vecchio; Patrick J Branigan; Elliot S Barnathan; Susan K Flavin; Philip E Silkoff; Ronald B Turner
Journal:  Pulm Pharmacol Ther       Date:  2014-11-13       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.